Publications by authors named "Cathy Bull"

Claim this Profile
D
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.
Jean-Marc Lapierre, Sudharshan Eathiraj, David Vensel, Yanbin Liu, Cathy O Bull

J Med Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
William J Scott, Martin F Hentemann, R Bruce Rowley, Cathy O Bull, Susan Jenkins, Ann M Bullion

ChemMedChem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Ningshu Liu, Bruce R Rowley, Cathy O Bull, Claudia Schneider, Andrea Haegebarth

Mol Cancer Ther· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Mark A Ashwell, Jean-Marc Lapierre, Christopher Brassard, Karen Bresciano, Cathy Bull

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis